Dr Joshua Savage

Dr Joshua Savage

Institute of Cancer and Genomic Sciences
Trial Management Team Leader

Contact details

Telephone
+44 (0)121 415 8421
Fax
+44 (0)121 414 3529
Email
j.savage.1@bham.ac.uk
View my research portal
Address
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Dr Joshua Savage is the Early Drug Development Trial Management Team Leader at the Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences at the University of Birmingham.

Qualifications

  • PhD Pharmacology, University of Bristol, 2012
  • BSc (Hons) Biochemistry, University of Bristol, 2008

Biography

Joshua Savage graduated with a BSc. (Hons) in Biochemistry from the University of Bristol in 2008. Following this he was awarded a Biotechnology and Biological Sciences Research Council studentship to study for a PhD at the University of Bristol, investigating the functional role of protein kinases in thrombosis in heart disease in the laboratory of Professor Alastair Poole in 2008.

Joshua joined the Adult Late Phase Team (B Team) of the Cancer Research UK Clinical Trials Unit at the University of Birmingham in 2013, coordinating academically sponsored late phase trials in skin (UKMCC-01, SPOT) and head & neck cancer (CompARE). In 2015 he was promoted to Senior Trial Coordinator within the B team, then later that year moved to the Children’s Cancer Trials Team.  Joshua worked primarily on international studies in the late phase solid tumour portfolio, focussing on Ewing’s sarcoma (EE2012, rEECur), rhabdomyosarcoma (RMS2005, FaR-RMS), and neuroblastoma (IMAT, HRNBL1), whilst also supporting the myeloid leukaemia study, MyeChild-01.

In 2018 Joshua was appointed as the EDD Trial Management Team Leader, and leads the trials team for a number of early phase cancer trials including the National Lung Matrix Trial, Tessa Jowell BRAIN MATRIX and ANICCA-Class II.

Joshua is the module co-lead of the Preparation and Set-up for a Clinical Trial module in MSc Clinical Trials.

Teaching

MSc Clinical Trials

Other activities

Publications

Highlight publications

Middleton, G, Fletcher, P, Popat, S, Savage, J, Summers, Y, Greystoke, A, Gilligan, D, Cave, J, O’rourke, N, Brewster, A, Toy, E, Spicer, J, Jain, P, Dangoor, A, Mackean, M, Forster, M, Farley, A, Wherton, D, Mehmi, M, Sharpe, R, Mills, TC, Cerone, MA, Yap, TA, Watkins, TBK, Lim, E, Swanton, C & Billingham, L 2020, 'The National Lung Matrix Trial of personalized therapy in lung cancer', Nature, vol. 583, no. 7818, pp. 807-812. https://doi.org/10.1038/s41586-020-2481-8

Middleton, G, Brock, K, Savage, J, Mant, R, Summers, Y, Connibear, J, Shah, R, Ottensmeier, C, Shaw, P, Lee, SM, Popat, S, Barrie, C, Barone, G & Billingham, L 2020, 'Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial', The Lancet Respiratory Medicine, vol. 8, no. 9, pp. 895-904. https://doi.org/10.1016/S2213-2600(20)30033-3

Williamson, SF, Grayling, MJ, Mander, AP, Noor, NM, Savage, JS, Yap, C & Wason, JMS 2022, 'Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information', Journal of Clinical Epidemiology, vol. 150, pp. 72-79. https://doi.org/10.1016/j.jclinepi.2022.06.017

Watts, C, Savage, J, Patel, A, Mant, R, Wykes, V, Pohl, U, Bulbeck, H, Apps, J, Sharpe, R, Thompson, G, Waldman, AD, Ansorge, O & Billingham, L 2022, 'Protocol for the Tessa Jowell BRAIN MATRIX Platform Study', BMJ open, vol. 12, no. 9, e067123. https://doi.org/10.1136/bmjopen-2022-067123

Menne, T, Slade, D, Savage, J, Johnson, S, Irving, J, Kearns, P, Plummer, R, Shenton, G, Veal, GJ, Vormoor, B, Vormoor, J & Billingham, L 2022, 'Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial', BMJ open, vol. 12, no. 3, e059872. https://doi.org/10.1136/bmjopen-2021-059872

Recent publications

Article

Mitchell, E, Goodman, K, Wakefield, N, Cochran, C, Cockayne, S, Connolly, S, Desai, R, Hartley, S, Lawton, S, Oatey, K, Rhodes, S, Savage, J, Taylor, J & Youssouf, N 2022, 'Clinical trial management: a profession in crisis?', Trials, vol. 23, no. 1, 357. https://doi.org/10.1186/s13063-022-06315-8

Love, SB, Cafferty, F, Snowdon, C, Carty, K, Savage, J, Pallmann, P, McParland, L, Brown, L, Masters, L, Schiavone, F, Hague, D, Townsend, S, Amos, C, South, A, Sturgeon, K, Langley, R, Maughan, T, James, N, Hall, E, Kernaghan, S, Bliss, J, Turner, N, Tutt, A, Yap, C, Firth, C, Kong, A, Mehanna, H, Watts, C, Hills, R, Thomas, I, Copland, M, Bell, S, Sebag-Montefiore, D, Jones, R, Parmar, MKB & Sydes, MR 2022, 'Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units', Trials, vol. 23, no. 1, 757. https://doi.org/10.1186/s13063-022-06680-4

Veenith, T, Fisher, BA, Slade, D, Rowe, A, Sharpe, R, Thickett, DR, Whitehouse, T, Rowland, M, Scriven, J, Parekh, D, Bowden, SJ, Savage, JS, Richards, D, Bion, J, Kearns, P, Gates, S & CATALYST Trial Investigators 2021, 'CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults', BMJ open, vol. 11, no. 11, e050202. https://doi.org/10.1136/bmjopen-2021-050202

Kong, A, Good, JS, Kirkham, A, Savage, J, Mant, R, Llewellyn, L, Parish, J, Spruce, R, Forster, M, Schipani, S, Harrington, K, Sacco, JJ, Murray, P, Middleton, G, Yap, C & Mehanna, H 2020, 'Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol', BMJ open, vol. 10, no. 3, e033009. https://doi.org/10.1136/bmjopen-2019-033009

Middleton, G, Fletcher, P, Popat, S, Savage, J, Summers, Y, Greystoke, A, Gilligan, D, Cave, J, O'Rourke, N, Brewster, A, Toy, E, Spicer, J, Jain, P, Dangoor, A, Mackean, M, Forster, M, Farley, A, Wherton, D, Mehmi, M, Sharpe, R, Mills, TC, Cerone, MA, Yap, TA, Watkins, TBK, Lim, E, Swanton, C & Billingham, L 2020, 'Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer', Nature. https://doi.org/10.1038/s41586-020-2656-3

Williams, CM, Savage, JS, Harper, MT, Moore, SF, Hers, I & Poole, AW 2016, 'Identification of roles for the SNARE-associated protein, SNAP29, in mouse platelets', Platelets, vol. 27, no. 4, pp. 286-294. https://doi.org/10.3109/09537104.2015.1100282

Golebiewska, EM, Harper, MT, Williams, CM, Savage, JS, Goggs, R, Von Mollard, GF & Poole, AW 2015, 'Syntaxin 8 regulates platelet dense granule secretion, aggregation, and thrombus stability', Journal of Biological Chemistry, vol. 290, no. 3, pp. 1536-1545. https://doi.org/10.1074/jbc.M114.602615

Moore, SF, Hunter, RW, Harper, MT, Savage, JS, Siddiq, S, Westbury, SK, Poole, AW, Mumford, AD & Hers, I 2013, 'Dysfunction of the PI3 kinase/Rap1/integrin aIIbb3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia', Blood, vol. 121, no. 7, pp. 1209-1219. https://doi.org/10.1182/blood-2012-05-431288

Letter

Harper, MT, Savage, JS & Poole, AW 2013, 'Comment on "Platelet-Derived Nucleotides Promote Tumor Cell Transendothelial Migration and Metastasis via P2Y2 Receptor" by Schumacher etal.', Cancer Cell, vol. 24, no. 3. https://doi.org/10.1016/j.ccr.2013.08.016

Savage, JS, Williams, CM, Konopatskaya, O, Hers, I, Harper, MT & Poole, AW 2013, 'Munc13-4 is critical for thrombosis through regulating release of ADP from platelets', Journal of Thrombosis and Haemostasis, vol. 11, no. 4, pp. 771-775. https://doi.org/10.1111/jth.12138

Preprint

Love, SB, Cafferty, F, Snowdon, C, Carty, K, Savage, J, Pallmann, P, McParland, L, Brown, LJ, Masters, L, Schiavone, F, Hague, D, Townsend, S, Amos, C, South, A, Sturgeon, K, Langley, RE, Maughan, TS, James, N, Hall, E, Kernaghan, S, Bliss, J, Turner, NC, Yap, C, Firth, C, Kong, A, Mehanna, H, Watts, C, Hills, R, Thomas, I, Copland, M, Bell, SE, Tutt, ANJ, Sebag-Montefiore, D, Jones, R, Parmar, MKB & Sydes, MR 2022 'Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units' Research Square. https://doi.org/10.21203/rs.3.rs-1195468/v1

Watts, C, Savage, J, Patel, A, Mant, R, Wykes, V, Pohl, U, Bulbeck, H, Apps, J, Sharpe, R, Thompson, G, Waldman, A, Ansorge, O, Billingham, L & Watts, C 2022 'Protocol for the Tessa Jowell BRAIN MATRIX Platform Study' medRxiv. https://doi.org/10.1101/2022.07.29.22277991

Williamson, SF, Grayling, MJ, Mander, AP, Noor, N, Savage, J, Yap, C & Wason, JMS 2022 'Subgroup analyses in randomised controlled trials frequently categorise continuous subgroup information' SSRN Electronic Journal, SSRN. https://doi.org/10.2139/ssrn.4077740

Veenith, T, Fisher, BA, Slade, D, Rowe, A, Sharpe, R, Thickett, DR, Whitehouse, T, Rowland, M, Scriven, J, Parekh, D, Bowden, SJ, Savage, JS, Richards, D, Bion, J, Kearns, P & Gates, S 2021 'CATALYST trial protocol: a multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults' medRxiv, pp. 1-15. https://doi.org/10.1101/2021.02.10.21251478

Menne, T, Slade, D, Savage, J, Johnson, S, Irving, JAE, Kearns, PR, Plummer, R, Shenton, G, Veal, GJ, Vormoor, B, Vormoor, J & Billingham, L 2021 'Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial' medRxiv. https://doi.org/10.1101/2021.10.22.21265327

View all publications in research portal